J. Buter
J. Buter
VU university Medical center
Verified email at
Cited by
Cited by
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised …
B Burtness, KJ Harrington, R Greil, D Soulières, M Tahara, G de Castro, ...
The Lancet 394 (10212), 1915-1928, 2019
Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial
H Mehanna, M Robinson, A Hartley, A Kong, B Foran, T Fulton-Lieuw, ...
The Lancet 393 (10166), 51-60, 2019
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 …
W Taal, HM Oosterkamp, AME Walenkamp, HJ Dubbink, LV Beerepoot, ...
The lancet oncology 15 (9), 943-953, 2014
The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature
JA Langendijk, CR Leemans, J Buter, J Berkhof, BJ Slotman
Journal of Clinical Oncology 22 (22), 4604-4612, 2004
Oral metastases: report of 24 cases
RIF Van der Waal, J Buter, I Van der Waal
British Journal of Oral and Maxillofacial Surgery 41 (1), 3-6, 2003
A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus
BM Tijink, J Buter, R De Bree, G Giaccone, MS Lang, A Staab, ...
Clinical Cancer Research 12 (20), 6064-6072, 2006
Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies
HT Mouridsen, SW Langer, J Buter, H Eidtmann, G Rosti, M De Wit, ...
Annals of Oncology 18 (3), 546-550, 2007
Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis
DT Sleijfer, RA Janssen, J Buter, EG De Vries, PH Willemse, NH Mulder
J Clin Oncol 10 (7), 1119-1123, 1992
Phase II study of 3-AP Triapine in patients with recurrent or metastatic head and neck squamous cell carcinoma
CM Nutting, CML Van Herpen, AB Miah, SA Bhide, JP Machiels, J Buter, ...
Annals of oncology 20 (7), 1275-1279, 2009
Malignant peripheral nerve sheath tumors in patients with and without neurofibromatosis
PF Doorn, WM Molenaar, J Buter, HJ Hoekstra
European Journal of Surgical Oncology (EJSO) 21 (1), 78-82, 1995
Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients
J Nieken, NH Mulder, J Buter, E Vellenga, PC Limburg, DA Piers, ...
18F-2-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography in Staging of Locally Advanced Breast Cancer
JJM Van Der Hoeven, NC Krak, OS Hoekstra, EFI Comans, RPA Boom, ...
Journal of clinical oncology 22 (7), 1253-1259, 2004
Intra‐arterial versus intravenous chemoradiation for advanced head and neck cancer: Results of a randomized phase 3 trial
CRN Rasch, M Hauptmann, J Schornagel, O Wijers, J Buter, T Gregor, ...
Cancer 116 (9), 2159-2165, 2010
Tumor volume as prognostic factor in chemoradiation for advanced head and neck cancer
JL Knegjens, M Hauptmann, FA Pameijer, AJ Balm, FJ Hoebers, ...
Head & neck 33 (3), 375-382, 2011
Salvage laryngectomy: oncological and functional outcome
L Van der Putten, R De Bree, DJ Kuik, DHF Rietveld, J Buter, ...
Oral oncology 47 (4), 296-301, 2011
The course of health-related quality of life in head and neck cancer patients treated with chemoradiation: a prospective cohort study
IM Verdonck-de Leeuw, LM Buffart, MW Heymans, DH Rietveld, ...
Radiotherapy and Oncology 110 (3), 422-428, 2014
Androgen deprivation therapy for androgen receptor‐positive advanced salivary duct carcinoma: a nationwide case series of 35 patients in The Netherlands
E Boon, W van Boxtel, J Buter, RJ Baatenburg de Jong, RJJ van Es, M Bel, ...
Head & neck 40 (3), 605-613, 2018
Identification of patients with recurrent glioblastoma who may benefit from combined bevacizumab and CCNU therapy: a report from the BELOB trial
L Erdem-Eraslan, MJ van den Bent, Y Hoogstrate, H Naz-Khan, A Stubbs, ...
Cancer research 76 (3), 525-534, 2016
Prevalence of swallowing and speech problems in daily life after chemoradiation for head and neck cancer based on cut-off scores of the patient-reported outcome measures SWAL …
RN Rinkel, IM Verdonck-de Leeuw, P Doornaert, J Buter, R de Bree, ...
European Archives of Oto-Rhino-Laryngology 273, 1849-1855, 2016
Cognitive functioning in glioblastoma patients during radiotherapy and temozolomide treatment: initial findings
K Hilverda, I Bosma, JJ Heimans, TJ Postma, W Peter Vandertop, ...
Journal of neuro-oncology 97, 89-94, 2010
The system can't perform the operation now. Try again later.
Articles 1–20